INC: Ipilimumab + Nivolumab + Ciforadenant in RCC
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
The University of Texas MD Anderson Cancer Center
Start Date
October 3, 2023
End Date
April 2, 2027
Administered By
Duke Cancer Institute
Awarded By
The University of Texas MD Anderson Cancer Center
Start Date
October 3, 2023
End Date
April 2, 2027